Despite the small number of randomized controlled trials with IL-1 inhibitors, they are strongly recommended in the treatment of Still’s disease due to the overwhelming body of evidence from real-world experience supporting their efficacy in controlling all aspects of the disease and to limit patients’ exposure to corticosteroids. This evidence concerns the gene IL1A and systemic-onset juvenile idiopathic arthritis.